Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in post-operative crohn's disease [0.03%]
空间转录组学揭示了术后克罗恩病所有解剖位置的独特炎症特征
Robert Battat,Bruno Sangiorgi,Bryan Linggi et al.
Robert Battat et al.
Background and aims: Most patients with Crohn's disease (CD) who have undergone ileocolonic resection experience recurrent inflammation within one year after surgery. We examined the molecular basis underlying gastrointes...
Development and Validation of a Novel patient-reported Outcome for Microscopic Colitis-Microscopic Colitis Score (MCS) [0.03%]
新型微观结肠炎患者报告结局的开发与验证-微观结肠炎评分(MCS)
Katarina Pihl Lesnovska,Samuel Schäfer,Yamile Zabana et al.
Katarina Pihl Lesnovska et al.
Background & aims: Despite debilitating symptoms, no standardized disease severity index exists for microscopic colitis (MC). This gap hinders alignment with US Food and Drug Administration (FDA) and European Medicines Ag...
How Long is Long Enough? Timing of Pre-conceptional Remission Predicts Relapse Risk During Pregnancy in IBD [0.03%]
多久才算足够长？孕前缓解的时机决定了炎症性肠病孕妇的复发风险
Dianne G Bouwknegt,Birgit Hoekstra,Hylke C Donker et al.
Dianne G Bouwknegt et al.
Background and aims: Inflammatory bowel disease often coincides with pregnancy, and disease activity during pregnancy increases the risk of adverse outcomes. We aimed to determine how disease course before conception infl...
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study [0.03%]
对于静脉使用维多珠单抗诱导治疗部分反应的炎症性肠病患者，换用皮下注射可能比强化静脉治疗获得更深层次缓解：PRIVEDO研究
Fabio Salvatore Macaluso,Walter Fries,Anna Viola et al.
Fabio Salvatore Macaluso et al.
Background: The optimal management of inflammatory bowel disease (IBD) patients with a partial response after intravenous (IV) vedolizumab (VDZ) induction remains unclear. ...
Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer [0.03%]
空间转录组学和免疫表型分析揭示了慢性炎症诱发的促进结肠炎相关癌症风险患者发育异常的免疫适应性
Sofía Frigerio,Hina N Khan,Mojtaba Amini et al.
Sofía Frigerio et al.
Background & aims: Colitis-associated cancer (CAC) is the most severe complication of inflammatory bowel disease (IBD). We hypothesized that chronic inflammation activates endogenous anti-inflammatory mechanisms that prom...
Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis [0.03%]
胰高血糖素样肽-1受体激动剂与炎症性肠病临床结局的关系：系统评价和.meta.分析
Ahmed B Bayoumy,Lindsay M Clarke,Parakkal Deepak et al.
Ahmed B Bayoumy et al.
Background: Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery and steroid-free remission. Glucagon-like peptide-1 receptor agonis...
Disease duration impacts intestinal gene expression profiles in crohn's disease but not in ulcerative colitis [0.03%]
病程影响克罗恩病肠道基因表达模式但不影响溃疡性结肠炎
Susanne Ibing,Christopher Tastad,Bernhard Y Renard et al.
Susanne Ibing et al.
Background: Disease duration is associated with lower treatment response and accrual of bowel damage in Crohn's disease (CD), but not in ulcerative colitis (UC). We aimed to understand intestinal transcriptomic changes as...
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers [0.03%]
新发炎症性肠病患者的全面蛋白质组谱分析：潜在生物标志物的鉴定
Montse Baldán-Martín,Ibon Iloro,Mikel Azkargorta et al.
Montse Baldán-Martín et al.
Objective: Identifying proteomic signatures in treatment-naïve individuals newly diagnosed with inflammatory bowel disease (IBD) may provide insights into the underlying pathophysiological mechanisms of the disease and a...